Indian River State College getting a new brand, customer experience. Voice your thoughts on college's new image.

Autism Together had rebranded with a new logo and design to “better represent the charity’s vision and the work it does to support autistic people”.

Paris: Sanofi and Dren Bio, Inc., a private clinical-stage biopharmaceutical company, have entered into a definitive agreement under which Sanofi has agreed to acquire DR-0201, a targeted bispecific ...

After the acquisition of Dren-0201, Dren Bio will continue to operate independently to advance its pipeline of antibody therapeutics that selectively deplete pathogenic cells and other disease ...

Sanofi is buy­ing a B cell-de­plet­ing an­ti­body de­vel­oped by Dren Bio as a ther­a­py for can­cer and au­toim­mune dis­eases.

PARIS, France I March 20, 2025 I Sanofi and Dren Bio, Inc., a private clinical-stage biopharmaceutical company, have entered into a definitive agreement under which Sanofi has agreed to acquire ...

Sanofi (NASDAQ:SNY) has struck a major deal to acquire Dren Bio’s autoimmune disease treatment, DR-0201, reinforcing its expansion in the biopharmaceutical sector. The French healthcare giant ...

(RTTNews) - Sanofi (SNY), a French pharmaceutical and healthcare company, announced on Thursday that it has entered into a definitive agreement to acquire Dren Bio, Inc.'s DR-0201, a targeted ...

Dren Bio deep B-cell depleter program has the potential to reset the immune system Acquisition underpins path for Sanofi becoming leading immunology company Sanofi to pay $600 million up front ...

Sanofi said it would acquire Bispecific Myeloid Cell Engager, an autoimmune disease treatment, from Dren Bio, for up to $1.9 billion. The French pharmaceutical company on Thursday said it would ...

In the latest move to cement its “immunology powerhouse” status, Sanofi is handing over $600 million upfront for Dren Bio’s clinical-stage bispecific antibody, with more than $1 billion in ...

Sanofi (SNY) and Dren Bio, a private clinical-stage biopharmaceutical company, have entered into a definitive agreement under which Sanofi has agreed to acquire DR-0201, a targeted bispecific ...